"Billions of dollars are spent every year on research into targeted therapies for cancer. That's why it's more than ever crucial for the thousands of scientists working in the field to keep right up to date with the cutting edge. This fascinating collection of material goes a long way to helping them do so, featuring as it does contributions to a crucial international meeting in Italy. The meeting provided a f ..."
"Billions of dollars are spent every year on research into targeted therapies for cancer. That's why it's more than ever crucial for the thousands of scientists working in the field to keep right up to date with the cutting edge. This fascinating collection of material goes a long way to helping them do so, featuring as it does contributions to a crucial international meeting in Italy. The meeting provided a f ..."
"After Phase I and II studies had suggested important activity for Sunitinib in GIST
patients failing Imatinib or being intolerant ... in a 2:1 randomization (Demetri,
Van Oosterom, Garrett, Blackstein, Shah, Verweij, McArthur, Judson, Heinrich,
Morgan, ... What the data on Sunitinib also show is that there may be a whole
range of other options for treatment of GIST. ... Interestingly, this has not only lead
to better results, but e ..."
"The text here offers readers an overview of diverse approaches, ranging from drug discovery to cellular therapy. Overall, the book addresses the key question of whether ultimately targeted therapy in cancer will be a myth or a reality."